5-Fluorouracil induce the expression of TLR4 on HCT116 colorectal cancer cell line expressing different variants of TLR4

Iranian Journal of Pharmaceutical Research

Volumn 12, Issue 2, 2013, Pages 453-460

  Davoodi, Homa ^a   Hashemi, Seyed Reza ^b   Seow, Heng Fong ^c  

^a GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b GORGAN UNIVERSITY OF AGRICULTURAL SCIENCES AND NATURAL RESOURCES   (Iran)

^c UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

5 FU; Chemotherapy; Colorectal cancer; Polymorphisms; TLR4

Indexed keywords

CASPASE 3; FLUOROURACIL; HIGH MOBILITY GROUP B1 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; TOLL LIKE RECEPTOR 4;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HCT116; COLORECTAL CANCER; CONTROLLED STUDY; CULTURE MEDIUM; ESCHERICHIA COLI; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING;

EID: 84878933247     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J and Schwartz DA. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. (2002) 347: 185-192.
2. Takeda K, Kaisho T and Akira S. Toll-like receptors. Annu. Rev. Immunol. (2003) 21: 335-76.
3. Levy RM, Mollen KP, Prince JM, Kaczorowski DJ, Vallabhaneni R, Liu S, Tracey KJ, Lotze MT, Hackam DJ, Fink MP, Vodovotz Y and Billiar TR. Systemic inflammation and remote organ injury following trauma require HMGB1. Am J. Physiol. Regul. Integr. Comp. Physiol. (2007) 293: 1538-1544.
4. Lorenz E, Mira JP Frees KL and Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch. Intern. Med. (2002) 162: 1028-1032.
5. Gergely PJR, Blazsek A, Weiszhár Z, Pazár B and Poór G. Lack of genetic association of the Toll-like receptor 4 (TLR4) Asp299Gly and Thr399Ile polymorphisms with spondylarthropathies in a Hungarian population. Rheumatology (2006) 45: 11946.
6. Ferwerda B, McCall MB, Verheijen K, Kullberg BJ, van der Ven AJ, Van der Meer JW and Netea MG. Functional consequences of toll-like receptor 4 polymorphisms. Mol. Med. (2008) 6: 346-352.
7. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL and Schwartz DA. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. (2000) 25: 187-191.
8. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, André F, Tursz T, Kroemer G and Zitvogel L. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Oncogene (2007) 2: 244-252.
9. Davoodi H and Seow HF. Variant Toll-Like receptor4 (Asp299Gly and Thr399Ile Alleles) and Toll-Like receptor2 (Arg753Gln and Arg677Trp Alleles) in colorectal cancer. Iran. J. Allergy Asthma Immunol. (2011) 10: 91-99.
10. Iacopetta B, Kawakami K and Watanabe T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int. J. Clin. Oncol. (2008) 6: 498-503.
11. De Angelis PM, Fjell B, Kravik KL, Haug T, Tunheim SH, Reichelt W, Beigi M, Clausen OP, Galteland E and Stokke T. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int. J. Oncol. (2004) 24: 1279-1288.
12. Park JS, Young Yoon S, Kim JM, Yeom YI, Kim YS and Kim NS. Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett. (2004) 214: 19-33.
13. Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF and Chiavaroli C. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur. J. Pharmacol. (2007) 563: 1-17.
14. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, Anton, PA, Gattinoni L, Rosenberg SA and Nicholas PR. Toll-like receptors in tumor immunotherapy. Clin. Cancer Res. (2007) 15: 5280-5289.
15. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Kroemer G and Zitvogel L. Tolllike receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. (2007) 9: 1050-1059.
16. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L and Kroemer G. Immunogenic cancer cell death: a keylock paradigm. Curr. Opin. Immunol. (2008) 20: 504-511.
17. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H and Tracey KJ. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. (2000) 192: 565-570.
18. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, Ishizaka A and Abraham E. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. (2006) 290: 917-924.
19. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G and Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. (2008) 68: 4026-30.
20. Ulukaya E, Colakogullari M and Wood EJ. Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay. Chemotherapy (2004) 50: 43-50.
21. Zhao L, Kwon MJ, Huang S, Lee JY, Fukase K, Inohara N, Hwang DH. Differential modulation of Nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells. J. Biol. Chem. (2007) 282: 11618-11628.
22. Suzuki M, Hisamatsu T and Podolsky DK. Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular Toll-Like Receptor 4-MD-2 complex. Infect. Immun. (2003) 71: 3503-3511.
23. nd ed., Birkhauser, Basel (2004) 520.
24. Hartford CM and Dolan ME. Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics (2007) 8: 1159-1168.
25. Tanaka S, Sakai A, Kimura K, Yoshida H, Fushitani H, Ogata A, Miyamoto A, Fukushima M, Wada A and Tanigawa N. Proteomic analysis of the basic proteins in 5-fluorouracil resistance of human colon cancer cell line using the radical-free and highly reducing method of two-dimensional polyacrylamide gel electrophoresis. Int. J. Oncol. (2008) 33: 361-70.
26. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A and Kroemer G. The anticancer immune response: indispensable for therapeutic success? J. Clin. Invest. (2008) 118: 1991-2001.
27. Krynetskaia N, Xie H, Vucetic S, Obradovic Z and Krynetskiy E. High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs. Mol. Pharmacol. (2007) 73: 260-269.
28. Sun Q, Liu Q, Zheng Y and Cao X. Rapamycin suppresses TLR4-triggered IL-6 and PGE (2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation. Mol. Immunol. (2008) 45: 2929-36.
29. He W, Liu Q, Wang L, Chen W, Li N and Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol. Immunol. (2007) 44: 2850-2859.
30. Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, Spaczynski M and Whiteside TL. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene (2009) 28: 4353-4363.